0.40Open0.40Pre Close0 Volume15 Open Interest5.00Strike Price0.00Turnover109.76%IV11.37%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier18DDays to Expiry0.40Extrinsic Value100Contract SizeAmericanOptions Type-0.3888Delta0.3035Gamma12.98Leverage Ratio-0.0134Theta-0.0011Rho-5.04Eff Leverage0.0044Vega
Pulmonx Stock Discussion
Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024
Pulmonx (Nasdaq: LUNG) presented clinical data from two significant studies at the European Respiratory Society Congress 2024. The AeriSeal® CONVERT trial showed that 77.6% of patients with collateral ventilation (CV+) successfully converted to CV- status after treatment with the AeriSeal System...
No comment yet